Skip to main content

textochbilcontainer

A BUSINESS MODEL WITH FASTER TIME TO MARKET AND LOWER DEVELOPMENT RISK COMPARED WITH CONVENTIONAL DRUG DEVELOPMENT

textochbilcontainer

RESULTS FROM THE TWO PHASE 3 STUDIES SHOW THAT MOB-015 HAS UNIQUE ANTIFUNGAL EFFECT

textochbilcontainer

Our goal is to get the first market approval for MOB ‐ 015 in 2023 in Europe.

Moberg Pharma is a rapidly growing Swedish pharmaceutical company commercializing proprietary, acquired and licensed products in the global market. Initially, the company specialized in the treatment of skin diseases, with a focus on treatments for nail fungus.

Stockvalue

Interview with CEO Anna Ljung
Peter
New pharmaceuticals for a global market

Subscribe

Get our latest press releases and reports

 

Latest report

2023-02-07 Moberg Pharmas Year-end report 2022

Calendar/presentations

Next calendar event: 2023-03-30 Swiss Nordic Bio, Zürich